PDCD1 and neoplasm: Sintilimab, a fully humanized immunoglobulin G4 anti-PD-1 monoclonal antibody, has demonstrated promising tolerability and anti-tumor activity in pediatric patients with advanced or recurrent malignancies in a phase I study (NCT04400851) (6).